Arbutus Biopharma CorpABUS
ASignal's systematic analysis rates ABUS as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ABUS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health with low debt-to-equity ratio (0.01x)
- High profitability margins: gross margin at 90.20% and net margin at 84.23%
- Exceptional return on equity (89.58%) indicating efficient capital use
- High cash position with $92.62M in total cash and minimal debt
- Current ratio of 81.42x suggests extreme liquidity strength
- RSI at 75.22 indicates overbought conditions
- Price trading above upper Bollinger Band (4.90) suggesting potential pullback
- Negative operating cash flow ($-24.62M) and free cash flow ($-80.24M)
- Severe year-over-year revenue decline (-90.60%)
- Negative operating margin (-567.16%) signaling operational distress
- Forward P/E of -30.13x reflects unprofitable future earnings expectations
See the full verdict on ABUS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABUS
Most investors never get a second opinion, let alone several. ASignal runs ABUS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.